Our Company

Ikena envisions a world where every cancer patient has a cure.

Ikena, headquartered in the biotech hub of Boston, Massachusetts, is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates.

Our name, Ikena, is derived from the combination of “I” which refers to the individual or the patient and “ken” which means understanding or knowledge, thereby illustrating our commitment to using our insights to identify which patients are most likely to benefit from our therapies. Ikena is also a Hawaiian word which means seeing, knowing, and having insight into the future. Our symbol further embodies our focus on pinpointing biomarkers that illuminate our knowledge into which patients may benefit from our therapies.

Today, our company is comprised of dedicated talented professionals who are striving to see, know, and understand what drives every patient’s cancer, with the ultimate goal of making a difference in patients’ lives.

Passion, innovation and courage
Passion, innovation, and courage are instrumental to Ikena’s continued progress towards accomplishing our mission and it is on those principles and values that Ikena is rapidly becoming a leader in the field of oncology.

Our History

Since our launch, we have achieved a number of milestones towards bringing novel biomarker-driven cancer therapies to patients.

Leading the charge to fully realize the potential of Ikena, for patients and for stakeholders.